Tobira Development Stock Price, News & Analysis (NASDAQ:TBRA)

$42.09 0.27 (0.65 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$41.82
Today's Range$40.39 - $42.33
52-Week Range$3.76 - $42.33
Volume521,800 shs
Average Volume251,055 shs
Market CapitalizationN/A
P/E Ratio-29.23
Dividend YieldN/A
BetaN/A

About Tobira Development (NASDAQ:TBRA)

Tobira Development logoTobira Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company's product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to liver damage. The Company’s pipeline also includes evogliptin, a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, which it plans to develop for NASH in combination with CVC.

Receive TBRA News and Ratings via Email

Sign-up to receive the latest news and ratings for TBRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:TBRA
CUSIPN/A
Phone+1-650-7416625

Debt

Debt-to-Equity Ratio0.44%
Current Ratio5.38%
Quick Ratio5.38%

Price-To-Earnings

Trailing P/E Ratio-29.2291666666667
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($1.44)
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-153.93%

Miscellaneous

Employees19
Outstanding Shares18,820,000

Tobira Development (NASDAQ:TBRA) Frequently Asked Questions

What is Tobira Development's stock symbol?

Tobira Development trades on the NASDAQ under the ticker symbol "TBRA."

How were Tobira Development's earnings last quarter?

Tobira Development Inc (NASDAQ:TBRA) released its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.08. The biopharmaceutical company had revenue of $1.06 million for the quarter, compared to analyst estimates of $0.15 million. View Tobira Development's Earnings History.

Who are some of Tobira Development's key competitors?

How do I buy Tobira Development stock?

Shares of Tobira Development can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tobira Development's stock price today?

One share of Tobira Development stock can currently be purchased for approximately $42.09.

How can I contact Tobira Development?

Tobira Development's mailing address is 701 Gateway Blvd Ste 200, SOUTH SAN FRANCISCO, CA 94080-7041, United States. The biopharmaceutical company can be reached via phone at +1-650-7416625.


MarketBeat Community Rating for Tobira Development (TBRA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about Tobira Development and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tobira Development (NASDAQ:TBRA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A2.80
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$86.80
Price Target Upside: N/AN/AN/A112.80% upside

Tobira Development (NASDAQ:TBRA) Consensus Price Target History

Price Target History for Tobira Development (NASDAQ:TBRA)

Tobira Development (NASDAQ:TBRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/22/2016Leerink SwannReiterated RatingOutperform$15.00 -> $45.00N/AView Rating Details
9/22/2016MizuhoReiterated RatingBuy$305.00N/AView Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> Hold$19.00 -> $42.00N/AView Rating Details
8/13/2016HC WainwrightReiterated RatingBuy$22.00 -> $31.00N/AView Rating Details
8/10/2016CowenReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Tobira Development (NASDAQ:TBRA) Earnings History and Estimates Chart

Earnings by Quarter for Tobira Development (NASDAQ:TBRA)

Tobira Development (NASDAQ TBRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216($0.63)($0.71)$0.15 million$1.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.53)($0.65)$0.11 millionViewN/AView Earnings Details
3/3/2016Q415($0.52)($0.50)ViewN/AView Earnings Details
11/10/2015Q315($1.00)($1.22)ViewListenView Earnings Details
8/11/2015Q215($0.99)ViewListenView Earnings Details
11/6/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/11/2014Q214($0.51)($0.63)ViewN/AView Earnings Details
5/14/2014Q114($0.62)($1.30)ViewN/AView Earnings Details
11/7/2013($0.43)($1.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Tobira Development (NASDAQ:TBRA) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Tobira Development (NASDAQ:TBRA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tobira Development (NASDAQ TBRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 62.42%
Insider Trades by Quarter for Tobira Development (NASDAQ:TBRA)
Insider Trades by Quarter for Tobira Development (NASDAQ:TBRA)

Tobira Development (NASDAQ TBRA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/31/2016Pentwater Capital Management LMajor ShareholderBuy15,000$41.84$627,600.00View SEC Filing  
10/18/2016Pentwater Capital Management LMajor ShareholderBuy40,000$40.06$1,602,400.00View SEC Filing  
10/17/2016Pentwater Capital Management LMajor ShareholderBuy31,700$40.07$1,270,219.00View SEC Filing  
10/4/2016Pentwater Capital Management LMajor ShareholderBuy4,481$39.83$178,478.23View SEC Filing  
9/29/2016Pentwater Capital Management LMajor ShareholderBuy15,519$39.49$612,845.31View SEC Filing  
9/26/2016Pentwater Capital Management LMajor ShareholderBuy50,000$39.00$1,950,000.00View SEC Filing  
9/23/2016Pentwater Capital Management LMajor ShareholderBuy100,000$39.19$3,919,000.00View SEC Filing  
9/22/2016Pentwater Capital Management LMajor ShareholderBuy1,624,200$39.04$63,408,768.00View SEC Filing  
7/13/2016A/S NovoMajor ShareholderSell59,067$12.02$709,985.341,914,541View SEC Filing  
7/7/2016A/S NovoMajor ShareholderSell92,119$12.20$1,123,851.802,016,691View SEC Filing  
6/30/2016A/S NovoMajor ShareholderSell66,814$13.04$871,254.562,073,022View SEC Filing  
6/6/2016A/S NovoMajor ShareholderSell187,500$10.37$1,944,375.002,093,905View SEC Filing  
3/4/2016A/S NovoMajor ShareholderSell190,000$6.80$1,292,000.002,361,405View SEC Filing  
11/18/2015A/S Novomajor shareholderSell225,000$9.79$2,202,750.002,471,405View SEC Filing  
5/4/2015A/S NovoMajor ShareholderBuy838,041$10.62$8,899,995.42View SEC Filing  
5/4/2015Parters Vii L P DomainMajor ShareholderBuy277,777$10.62$2,949,991.74View SEC Filing  
4/16/2014Robert Kierlinmajor shareholderBuy575,000$6.00$3,450,000.004,284,955View SEC Filing  
2/5/2014Robert Kierlinmajor shareholderBuy400,000$5.00$2,000,000.003,700,955View SEC Filing  
8/27/2013Raphael WisniewskiDirectorBuy1,215,708$4.00$4,862,832.00View SEC Filing  
8/27/2013Rmi Investments S.A.R.L.Major ShareholderBuy3,866,529$4.00$15,466,116.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tobira Development (NASDAQ TBRA) News Headlines

Source:
DateHeadline
ADMA Biologics (ADMA) versus Tobira Development (TBRA) Head-To-Head ContrastADMA Biologics (ADMA) versus Tobira Development (TBRA) Head-To-Head Contrast
www.americanbankingnews.com - December 30 at 5:20 AM
Financial Comparison: Rigel Pharmaceuticals (RIGL) versus Tobira Development (TBRA)Financial Comparison: Rigel Pharmaceuticals (RIGL) versus Tobira Development (TBRA)
www.americanbankingnews.com - November 25 at 5:12 PM
Financial Contrast: Tobira Development (TBRA) vs. The CompetitionFinancial Contrast: Tobira Development (TBRA) vs. The Competition
www.americanbankingnews.com - September 18 at 8:34 PM
Sarepta Therapeutics (SRPT) and Tobira Development (TBRA) Financial ContrastSarepta Therapeutics (SRPT) and Tobira Development (TBRA) Financial Contrast
www.americanbankingnews.com - September 7 at 12:06 AM
Tobira Therapeutics (NASDAQ:TBRA) vs. Radius Health (RDUS) Head to Head ContrastTobira Therapeutics (NASDAQ:TBRA) vs. Radius Health (RDUS) Head to Head Contrast
www.americanbankingnews.com - July 15 at 6:20 PM
The Lesson in Straight Paths Short SqueezeThe Lesson in Straight Path's Short Squeeze
www.bloomberg.com - May 11 at 11:06 PM
Biotech Forum Daily Digest: Upward Resistance Levels Continue To Hold; Spotlight On Foamix PharmaceuticalsBiotech Forum Daily Digest: Upward Resistance Levels Continue To Hold; Spotlight On Foamix Pharmaceuticals
seekingalpha.com - March 4 at 1:11 AM
Allergan Hints It Is Ready to Make a Splash for More Near-term GrowthAllergan Hints It Is Ready to Make a Splash for More Near-term Growth
us.rd.yahoo.com - January 11 at 5:38 AM
Biotech Stocks on Investors Radar -- Agenus, Portola Pharma, Tobira Therapeutics, and Auris Medical - PR Newswire (press release)Biotech Stocks on Investors' Radar -- Agenus, Portola Pharma, Tobira Therapeutics, and Auris Medical - PR Newswire (press release)
www.prnewswire.com - November 1 at 12:21 PM
TOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of AcquisitiTOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisiti
biz.yahoo.com - November 1 at 12:21 PM
Notable Thursday Option Activity: TBRA, CRUS, BCOR - NasdaqNotable Thursday Option Activity: TBRA, CRUS, BCOR - Nasdaq
www.nasdaq.com - October 28 at 11:39 AM
Notable Thursday Option Activity: TBRA, CRUS, BCORNotable Thursday Option Activity: TBRA, CRUS, BCOR
www.nasdaq.com - October 27 at 7:46 PM
Allergan CEO Brent Saunders Succeeds Paul Bisaro as ChairmanAllergan CEO Brent Saunders Succeeds Paul Bisaro as Chairman
www.wsj.com - October 26 at 7:37 PM
Tobira Therapeutics (TBRA) Presents Phase 2b CENTAUR Year 1 Analysis at AASLD Annual MeetingTobira Therapeutics (TBRA) Presents Phase 2b CENTAUR Year 1 Analysis at AASLD Annual Meeting
www.streetinsider.com - October 20 at 7:55 PM
Tobira Therapeutics Announces Late-Breaking Oral...Tobira Therapeutics Announces Late-Breaking Oral...
www.benzinga.com - October 20 at 12:45 PM
Allergan (AGN) Announces Early HSR Act Termination in Proposed Merger with TobiraAllergan (AGN) Announces Early HSR Act Termination in Proposed Merger with Tobira
www.streetinsider.com - October 19 at 7:13 PM
FTC Grants Early Termination Of HSR Waiting Period For Allergan-Tobira DealFTC Grants Early Termination Of HSR Waiting Period For Allergan-Tobira Deal
www.nasdaq.com - October 19 at 10:50 AM
Controversy Over Allergans 500% Premium for Tobira Looks OverdoneControversy Over Allergan's 500% Premium for Tobira Looks Overdone
www.thestreet.com - October 12 at 7:35 PM

SEC Filings

Tobira Development (NASDAQ:TBRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tobira Development (NASDAQ:TBRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tobira Development (NASDAQ TBRA) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.